Financial highlights

Five year performance
Five Year Performance

2008
Five Year Performance
Five Year Performance

2008-New market product launches
Shire Australia

Specialty Pharmaceuticals ('SP') (FOSRENOL and XAGRID) and Human Genetic Therapies ('HGT') products (REPLAGAL) taken back from local distributors and re-launched under Shire.

Shire Brazil

HGT products to be commercialized directly via the Local Operating Company ('LOC').

Shire Czech Republic

HGT products-ELAPRASE and REPLAGAL.

Shire Greece

HGT products-ELAPRASE and REPLAGAL.

Shire Japan

Local rep office will work with existing partners to optimize commercialization of Shire portfolio: Genzyme Corporation for ELAPRASE, Dainippon Sumitomo Pharma Co., Ltd for REPLAGAL, Mochida Pharmaceutical Co., Ltd for LIALDA, Bayer Yakuhin Ltd for FOSRENOL, Kirin Brewery Company Ltd for XAGRID.

Shire Mexico

HGT products to be commercialized directly via the LOC, FOSRENOL commercialization plans through a local distributor.

Shire Russia

HGT products to be commercialized directly via the rep office; FOSRENOL, AGRYLIN and MEZAVANT to be commercialized via relationship with commercial partner.